Hepatology

Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies

EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.

EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment

EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.

EASL 2026 Forum: Enhancing Patient-Clinician Communication

The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.

EASL 2026: Alcohol Policy Action Needed for Liver Disease

The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.

A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis

New A-TANGO organ failure score refines acute-on-chronic liver failure (ACLF) diagnosis and prognostication in hospitalised cirrhosis patients.

MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines

Despite 2024 EASL guidelines for MASLD, physicians encounter significant barriers in screening and diagnosis, particularly in SEEMEA.

EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging

EASL 2026 highlights the evolving role of non-invasive diagnostics in liver disease, offering improved accuracy for fibrosis and steatosis assessment.

Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined

Late-onset genetic cholestatic diseases are frequently missed in adults, leading to delayed diagnosis and suboptimal management. Increased awareness is critical.

HDV Management: EASL 2026 Highlights PegIFN-α as Standard

EASL 2026 discussions reaffirmed peginterferon alfa as the cornerstone of HDV management, with emerging therapies showing promise.

MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026

Experts at EASL 2026 discussed the distinct challenges of managing advanced fibrosis in MASH, highlighting diagnostic and therapeutic complexities.